Compare AVLN & RDWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVLN | RDWR |
|---|---|---|
| Founded | 2011 | 1996 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2026 | 2000 |
| Metric | AVLN | RDWR |
|---|---|---|
| Price | $26.27 | $30.96 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $61.80 | $30.50 |
| AVG Volume (30 Days) | ★ 266.3K | 258.6K |
| Earning Date | 11-25-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $10.09 |
| Revenue Next Year | N/A | $7.92 |
| P/E Ratio | ★ N/A | $59.76 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.24 | $21.68 |
| 52 Week High | $40.17 | $32.79 |
| Indicator | AVLN | RDWR |
|---|---|---|
| Relative Strength Index (RSI) | 45.32 | 57.77 |
| Support Level | $24.90 | $26.53 |
| Resistance Level | $30.45 | $32.01 |
| Average True Range (ATR) | 1.73 | 1.48 |
| MACD | 0.45 | 0.07 |
| Stochastic Oscillator | 72.23 | 85.61 |
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
Radware Ltd is a provider of application security and delivery solutions for multi-cloud environments. Its solutions secure the digital experience by providing infrastructure, application, and network protection and availability services to companies globally. Its solutions are deployed by, among others, enterprises, carriers, and cloud service providers. The company offers solutions in two main categories: Products offers a range of cloud-based security-as-a-service subscriptions, on-premises hardware and software products, and product subscriptions (or a combination of these) to customers; and Services offers managed services, professional services, technical support and training and certification to customers and partners.